Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us Donate
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
    All Public Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Healthcare Helpline
    • KFF Health News Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • Common Ground
    • Diagnosis: Debt
    • Eleven Minutes
    • Priced Out
    • Data Grab
    • Memory Gaps
    • Growing Up Scared
    • Denied
    • Opioid Settlement Tracking
    • Guns, Race, and Profit
    All Special Reports
  • More Topics

    More Topics

    • Elections
    • Healthcare Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health
    All Topics

  • Medicare Advantage Billing Probe
  • School Vaccine Mandates
  • Weight Loss Drugs Coverage
  • Opioid Settlement Money
  • Abortion Pill Access

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email
  • Add Us to Google

Wednesday, Nov 18 2026 UPDATED 9:24 AM

Full Issue

Viewpoints: First Political Battles Of 2027 Should Tackle Medicaid, RFK Jr. Impeachment; Measles Deaths Are A Preventable Tragedy

Opinion writers discuss these public health topics.

Bloomberg: Medicaid Expansion Will Be The First Big Political Fight Of 2027

November’s big Democratic wins in state races could empower the party to close the largest remaining gap in America’s healthcare safety net: Medicaid, the joint state-federal program providing healthcare for low-income Americans. Ten states have long refused to expand it, and Democrats have new power in several of them, including Texas, Georgia and Wisconsin. (Ronald Brownstein, 11/17)

Stat: Why Now Is The Time To Impeach HHS Secretary Robert Kennedy Jr. 

The midterms didn’t just bring a blue wave — it was a biomedical blue wave, with several doctors and scientists joining Congress. This moment presents a unique opportunity to remove a major American public health problem. I’m talking about impeaching Health and Human Services Secretary Robert F. Kennedy Jr. once the next Congress begins in January. (Paul Knoepfler, 11/18)

The New York Times: An Elegy For Americans Dying Of Measles 

America has officially lost its measles elimination status. (Perri Klass, 11/17)

CNN: Dr. Sanjay Gupta: Benefits Of Vaccines Are A Matter Of Fact 

I have started, scratched out and even abandoned the writing of this essay. I couldn’t do it. It wasn’t there. Didn’t feel it. Something kept nagging at me, and it took some time to finally figure out what it was. It’s the idea that this article would be labeled “opinion” or “editorial” in the first place. Sure, there are some topics that seem to lend themselves appropriately to opinion pages. Vaccines, however, which have prevented 6 million deaths every year worldwide and have fundamentally changed modern medicine, should not be on that list. (Dr. Sanjay Gupta, 11/17)

Stat: A Radical Way To Transform Medical Education 

Over eight years as an M.D./Ph.D. student, I have watched medical education change considerably. Preclinical curricula have become shorter, lectures have moved online, virtual reality tools have entered anatomy education, and licensing examinations have repeatedly changed. (Alex Serafini, 11/18)

Stat: Sellas Blood Cancer Immunotherapy Succeeds In Clinical Trial 

It looks like I was wrong about Sellas Life Sciences and its experimental blood cancer immunotherapy. On Tuesday, Sellas said the therapy, called galinpepimut-S, reduced the risk of death by 41% compared to standard treatment for patients with an advanced stage of acute myeloid leukemia (AML) — an outcome that achieved the main goal of a Phase 3 clinical trial, the company said. (Adam Feuerstein, 11/17)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Today, November 18
  • Tuesday, November 17
  • Monday, November 16
  • Friday, November 13
  • Thursday, November 12
  • Tuesday, November 10
More Morning Briefings
RSS Feeds
  • Podcasts
  • Special Reports
  • Morning Briefing
  • About Us
  • Donate
  • Staff
  • Republish Our Content
  • Contact Us

Follow Us

  • Instagram
  • YouTube
  • LinkedIn
  • Facebook
  • X
  • Bluesky
  • TikTok
  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

© 2026 KFF